Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.68 |
| ▸ | HPGD | P15428 | 5/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 5/20 | 0.52 |
| ▸ | RAB9A | P51151 | 4/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | GFER | P55789 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | F2 | P00734 | 1/20 | 0.49 |
| ▸ | F10 | P00742 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL457785 | 0.95 | ALDH1A1 (0.75) | ALDH1A1HPGDMAPTNPC1RAB9A | |
| SCHEMBL322211 | 0.85 | ALDH1A1 (0.93) | ALDH1A1HPGDMAPTNPC1RAB9A | |
| SCHEMBL6236939 | 0.83 | ALDH1A1 (0.68) | ALDH1A1HPGDMAPTNPC1RAB9A | |
| SCHEMBL25676615 | 0.83 | ALDH1A1 (0.68) | ALDH1A1HPGDMAPTNPC1RAB9A | |
| SCHEMBL505844 | 0.83 | ALDH1A1 (0.90) | ALDH1A1HPGDMAPTNPC1RAB9A | |
| SCHEMBL70639 | 0.81 | ALDH1A1 (1.00) | ALDH1A1HPGDNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4195522 | 0.80 | ALDH1A1 (0.62) | ALDH1A1HPGDMAPTNPC1RAB9A | |
| SCHEMBL2644969 | 0.79 | ALDH1A1 (0.61) | ALDH1A1HPGDMAPTNPC1RAB9A | |
| SCHEMBL2725729 | 0.79 | MAPT (0.59) | ALDH1A1HPGDMAPTLMNAF10 | |
| SCHEMBL4690924 | 0.78 | HPGD (0.61) | ALDH1A1HPGDMAPTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200140436-A1 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-05-07 | — | — | US | disclosed |
| CN-110894196-A | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | 百时美-施贵宝控股爱尔兰无限公司 | 2020-03-20 | — | — | CN | disclosed |
| US-10544150-B2 | NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders | OGEDA SA (BE) | 2020-01-28 | — | — | US | disclosed |
| US-10065960-B2 | NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders | OGEDA SA (BE) | 2018-09-04 | — | — | US | disclosed |
| US-20180244673-A1 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-08-30 | — | — | US | disclosed |
| US-20180194772-A1 | NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS | OGEDA SA (BE) | 2018-07-12 | — | — | US | disclosed |
| US-9975891-B2 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-22 | — | — | US | disclosed |
| US-9926325-B2 | NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders | OGEDA SA (BE) | 2018-03-27 | — | — | US | disclosed |
| EP-3176171-A1 | NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS | OGEDA SA (BE) | 2017-06-07 | — | — | EP | disclosed |
| EP-2552920-B1 | NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS | OGEDA SA (BE) | 2017-03-15 | — | — | EP | disclosed |
| US-20050261287-A1 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-11-24 | — | — | US | disclosed |
| US-6967208-B2 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-11-22 | — | — | US | disclosed |
| EP-1427415-A4 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2005-11-02 | — | — | EP | disclosed |
| US-20050171085-A1 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-08-04 | — | — | US | disclosed |
| US-20050124602-A1 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-06-09 | — | — | US | disclosed |
| CN-1578660-A | Lactam-containing compounds and derivatives thereof as factor xa inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2005-02-09 | — | — | CN | disclosed |
| US-20040220174-A1 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-04 | — | — | US | disclosed |
| EP-1427415-A1 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | Bristol-Myers Squibb Company (US) | 2004-06-16 | — | — | EP | disclosed |
| US-20030191115-A1 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-10-09 | — | — | US | disclosed |
| WO-2003026652-A1 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180244673-A1 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | F12, F2, CPB1 | ALDH1A1 3371/4885HPGD 2070/4885MAPT 4680/4885 |
| US-10065960-B2 | NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders | BDKRB2, ACKR3, KLRK1 | ALDH1A1 3468/4885HPGD 2000/4885MAPT 4528/4885 |
| US-20180194772-A1 | NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS | ACKR3, BDKRB2, GPR3 | ALDH1A1 3636/4885HPGD 2329/4885MAPT 4547/4885 |
| US-20050261287-A1 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | F12, F2, CPB1 | ALDH1A1 3371/4885HPGD 2070/4885MAPT 4680/4885 |
| US-20040220174-A1 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | PEPD, PRSS1, CPB1 | ALDH1A1 3520/4885HPGD 1830/4885MAPT 4597/4885 |
| US-20050124602-A1 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | F12, F2, CPB1 | ALDH1A1 3406/4885HPGD 2131/4885MAPT 4664/4885 |
| US-20050171085-A1 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | F12, F2, CPB1 | ALDH1A1 3371/4885HPGD 2070/4885MAPT 4680/4885 |
| US-20200140436-A1 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | F12, F2, CPB1 | ALDH1A1 3406/4885HPGD 2131/4885MAPT 4664/4885 |
| US-20030191115-A1 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | PEPD, HABP2, CPB1 | ALDH1A1 2453/4885HPGD 1207/4885MAPT 4569/4885 |
| US-10544150-B2 | NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders | BDKRB2, ACKR3, KLRK1 | ALDH1A1 3468/4885HPGD 2000/4885MAPT 4528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.